NAD referral
This article was originally published in The Tan Sheet
Executive Summary
Advertising for BIE Health Products' GHR "human-growth hormone 'releaser'" has been referred to the Federal Trade Commission and FDA since the firm declined to adequately participate in the National Advertising Division's self-regulatory forum, NAD states July 17. The Council of Better Business Bureaus division identified suspect claims for GHR such as "reversal of many degenerative disease symptoms" and "increased bone density" through its routine and ongoing monitoring program. Although BEI agreed to "provide evidence for review under criteria dictated by BIE," the firm's refusal to participate in NAD's forum according to established procedures leads NAD to refer the ad claims to FTC and FDA for "possible law enforcement action," NAD says...